Indatraline-conjugated ASO (IND-ASO), designed to inhibit SNCA, improved dopamine neurotransmission in a PD-like mouse model and elderly nonhuman primates after ICV and intranasal administration (Alarcón-Arís et al., 2020, section 1.7.1). Here, SNCA is linked to Parkinson disease.